Journal Watch · Proceedings of the National Academy of Sciences (PNAS) · 2026

Polycomb Repressive Complex 2 drives flow-sensitive endothelial states underlying vascular inflammation and disease.

This study elucidates a fundamental epigenetic mechanism in vascular inflammation and suggests a potential treatment for advanced and chronic cardiovascular inflammatory diseases.

Joshi D, Rukhlenko O, Chakraborty R et al.Proceedings of the National Academy of Sciences (PNAS)3 min readPharma relevance 60/100

DOI: 10.1073/pnas.2603888123PMID: 42673460Study type: preclinical (animal / model) study

TL;DR

This study elucidates a fundamental epigenetic mechanism in vascular inflammation and suggests a potential treatment for advanced and chronic cardiovascular inflammatory diseases.

Key findings

  • Integrated mechanistic computation and experimental studies identified PRC2 as a central determinant of the EC state transition to inflammatory activation.
  • PRC2 activity is elevated in endothelium from human ASCVD lesions.
  • In murine models of acute and chronic vascular inflammation, interventional treatment with tazemetostat, a Federal Drug Administration (FDA)-approved inhibitor of the PRC2 methyltransferase EZH2, reduced endothelial inflammatory genes, slowed disease progression, and drastically improved markers of plaque stability.
  • This study elucidates a fundamental epigenetic mechanism in vascular inflammation and suggests a potential treatment for advanced and chronic cardiovascular inflammatory diseases.

What they did

However, the central determinants of endothelial inflammatory mechanotransduction and their interventional targeting to treat ASCVD pathology remain underexplored. Here, we identify Polycomb Repressive Complex (PRC) 2 as a potent, therapeutically targetable driver of vascular endothelial inflammation and ASCVD progression. PRC2 trimethylates Histone H3 Lysine27 in gene promoters/enhancers, including Klf2/4, to block gene transcription.

Full abstract (original)

Background: Atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality worldwide, is driven by endothelial cell (EC) inflammatory activation and counterbalanced by protective mechanosensitive transcription factors Klf2 and Klf4 (Klf2/4). Plaques initiate in arterial curves or branches where disturbed shear stress (DSS) restrains Klf2/4 expression and promotes inflammatory activation of the endothelium. Importantly, DSS determines plaque vulnerability to rupture, the event that precipitates heart attack or stroke in advanced disease.

What they did: However, the central determinants of endothelial inflammatory mechanotransduction and their interventional targeting to treat ASCVD pathology remain underexplored. Here, we identify Polycomb Repressive Complex (PRC) 2 as a potent, therapeutically targetable driver of vascular endothelial inflammation and ASCVD progression. PRC2 trimethylates Histone H3 Lysine27 in gene promoters/enhancers, including Klf2/4, to block gene transcription.

Results & conclusions: Integrated mechanistic computation and experimental studies identified PRC2 as a central determinant of the EC state transition to inflammatory activation. PRC2 activity is elevated in endothelium from human ASCVD lesions. In murine models of acute and chronic vascular inflammation, interventional treatment with tazemetostat, a Federal Drug Administration (FDA)-approved inhibitor of the PRC2 methyltransferase EZH2, reduced endothelial inflammatory genes, slowed disease progression, and drastically improved markers of plaque stability. This study elucidates a fundamental epigenetic mechanism in vascular inflammation and suggests a potential treatment for advanced and chronic cardiovascular inflammatory diseases.

Abstract © the authors / Proceedings of the National Academy of Sciences (PNAS) (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1073/pnas.2603888123 · PubMed 42673460.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Proceedings of the National Academy of Sciences (PNAS) study find?

This study elucidates a fundamental epigenetic mechanism in vascular inflammation and suggests a potential treatment for advanced and chronic cardiovascular inflammatory diseases.

What type of study is this?

It is a preclinical (animal / model) study, published in Proceedings of the National Academy of Sciences (PNAS) in 2026. However, the central determinants of endothelial inflammatory mechanotransduction and their interventional targeting to treat ASCVD pathology remain underexplored.

Where can I read the original paper?

The original is at the publisher via DOI 10.1073/pnas.2603888123. PubMed ID: 42673460. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Joshi D, Rukhlenko O, Chakraborty R et al.. Polycomb Repressive Complex 2 drives flow-sensitive endothelial states underlying vascular inflammation and disease.. Proceedings of the National Academy of Sciences (PNAS) (2026). DOI: 10.1073/pnas.2603888123.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/polycomb-repressive-complex-2-drives-flow-sensitive-endothelial-states-u-888123/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides